The Medicines and Healthcare Products Regulatory Agency (MHRA) has for the first time approved the use of a dual (ICS/Formoterol) combination treatment to be used as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an alterna

PCRS advocate a pragmatic approach to the pharmacological management of patients with COPD guided by the predominance of breathlessness and/or exacerbations and the presence or absence of comorbid asthma.

Biologics are a class of medications that are specifically designed to target and modify specific components

A new report is showcasing the impact of a national AHSN Network programme to improve access to FeNO testing for asthma diagnosis.

Dr Iain Small (Chair of the Primary Care Respiratory Society 2008 – 2013) (Born 11/02/1961 Died 20/06/2023)

Lung Volume Reduction (LVR) is a clinically proven and NICE approved therapy for reducing breathlessness in COPD. Changes in treatment means that minimally invasive options (e.g. valves) are now available, but the majority of eligible patients are not referred.

Viv Marsh (Asthma Nurse Specialist) is joined by Amanda Roberts (PCRS Patient Reference Group and PCRS Education Committee Patient Representative) to discuss all things Asthma Action Plans in this episode of the PCRS Podcast.

The PCRS Patient Reference Group (PRG) is a small group of people with respiratory conditions who support PCRS to ensure that we always try to embed the patient perspective in our work and consider the holistic management of patients.

Have you booked your place at this year’s conference yet? Early bird registration is now open for you to secure your place and join us in Telford for the UK’s leading respiratory conference for clinicians working in primary, community, and integrated care.

This pragmatic guide focuses on the ongoing management of adults and children with severe asthma receiving biologic therapy and has been developed by an expert group led by Will Carroll, University Hospital of the North Midlands, Stoke-on-Trent and including Ernie Wong, Imperial College Healthcar

In an ideal world, asthma review appointments will be between 20 to 30 minutes in duration. But we are not living in an ideal world.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has for the first time approved the use of a dual (ICS/beta-agonist) combination treatment to be prescribed as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an